A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Recruiting
Loxo Oncology, Inc.
Phase 3
2021-09-20
The purpose of this study is to compare the efficacy and safety of fixed duration
pirtobruitinib (LOXO-305) with VR (Arm A) compared to VR alone (Arm B) in patients with
CLL/SLL who have been previously treated with at least one prior line of therapy.
Participation could last up to five years.
A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Recruiting
Loxo Oncology, Inc.
Phase 3
2021-09-23
The purpose of this study is to compare the efficacy and safety of pirtobrutinib (LOXO-305;
Arm A) compared to BR (Arm B) in patients with CLL/SLL who have not been treated.
Participation could last up to five years.
Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia
Not yet recruiting
Incyte Corporation
Phase 2
2023-01-01
This phase II clinical trial tests a chemotherapy regimen (dose-adjusted etoposide,
prednisone, vincristine, cyclophosphamide and doxorubicin with or without rituximab
[DA-EPOCH+/-R]) with the addition of targeted therapy (tafasitamab) for the treatment of
patients with newly diagnosed Philadelphia chromosome negative (Ph-) B acute lymphoblastic
leukemia (B-ALL). Chemotherapy drugs, such as those in EPOCH+/-R, work in different ways to
stop the growth of cancer cells, either by killing the cells, by stopping them from dividing,
or by stopping them from spreading. Tafasitamab is in a class of medications called
monoclonal antibodies. It works by helping the body to slow or stop the growth of cancer
cells. Adding tafasitamab to the DA-EPOCH+/-R regimen may work better than DA-EPOCH+/-R alone
in treating newly diagnosed Ph- B-ALL.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
